Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,037 | -33,017 | -22,370 | -12,896 | -5,129 |
| Depreciation Amortization | 182 | 699 | 538 | 317 | 137 |
| Other Working Capital | -5,215 | 38,167 | 36,438 | 33,870 | -1,210 |
| Other Operating Activity | 993 | 2,795 | 1,816 | 846 | 421 |
| Operating Cash Flow | $-15,077 | $8,644 | $16,422 | $22,137 | $-5,781 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -76 | -366 | -350 | -277 | -7 |
| Investing Cash Flow | $-76 | $-366 | $-350 | $-277 | $-7 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -1 | -49 | -48 | -45 | -22 |
| Common Stock Issued | 771 | 23,158 | 18,264 | 16,686 | N/A |
| Financing Cash Flow | $770 | $23,109 | $18,216 | $16,641 | $-22 |
| Beginning Cash Position | 109,608 | 78,221 | 78,221 | 78,221 | 78,221 |
| End Cash Position | 95,225 | 109,608 | 112,509 | 116,722 | 72,411 |
| Net Cash Flow | $-14,383 | $31,387 | $34,288 | $38,501 | $-5,810 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,077 | 8,644 | 16,422 | 22,137 | -5,781 |
| Capital Expenditure | -76 | -366 | -350 | -277 | -7 |
| Free Cash Flow | -15,153 | 8,278 | 16,072 | 21,860 | -5,788 |